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Patients with end-stage heart failure have a very poor
prognosis with standard medical therapy, with survival rates
as low as 25% at 1 year and 8% at 2 years (1). For those who
qualify, heart transplantation is the therapy of choice, but it
is often delayed because of the critical shortage of donor
hearts. Left ventricular assist devices (LVADs) were devel-
oped for temporary support of the terminally failing ventricle
until a suitable donor heart became available (bridge to
transplant [BTT] indication). Their use was subsequently
expanded to include selected patients with end-stage heart
failure who are not candidates for heart transplantation
(destination therapy [DT] indication).See page 880Implantable LVADs include a pump housing chamber, an
external controller, a driveline that connects the two, and
rechargeable batteries. First-generation implantable LVADs
were initially conceived as pulsatile devices, but they were
bulky in size and had limited durability. These concerns were
overcome by the development of continuous ﬂow LVADs,
which have markedly improved durability and signiﬁcantly
smaller dimensions compared with their predecessors.
Continuous ﬂow LVADS are technological marvels that
have revolutionized the care of patients with end-stage heart
failure. Recent studies show that the 1-year survival is 73%
for patients receiving implantation as DT (2), and 85% for
those receiving implantation as BTT (3), which matches the
1-year survival after heart transplantation. Importantly, this
improved survival is accompanied by a marked improvement
in quality of life and functional capacity (4). Thus, the*Editorials published in the Journal of the American College of Cardiology reﬂect the
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rising, and the duration of support on LVAD is steadily
increasing, because a growing number of patients are being
implanted as DT.
Complications after LVAD implantation include the
usual morbidities associated with cardiac surgery as well as
device-related events such as driveline infections and right
ventricular failure. Patients with LVADs are also at risk for
ischemic neurological events and pump thrombosis, so they
are usually maintained on anticoagulant and antiplatelet
medications. However, these patients also have an increased
risk of bleeding, because continuous ﬂow physiology is
associated with platelet dysfunction and acquired von Wil-
lebrand syndrome (5). The most common site of bleeding is
the gastrointestinal tract, but the most feared site is the
intra-cranium.
In this issue of the Journal, Boyle et al. (6) provide valu-
able insights into the bleeding and thrombotic complications
associated with LVAD implantation. They evaluated the
pre-operative risk factors that were independent predictors
of bleeding, hemorrhagic stroke, ischemic stroke, and pump
thrombosis, among patients enrolled in the landmark
HeartMate II (Thoratec, Inc., Pleasanton, California) BTT
(7) and DT (8) clinical trials. This retrospective analysis
included 956 patients (220 women, 23%) who were being
implanted with the HeartMate II device and who survived
to hospital discharge. During a median follow-up of 1.5
years, 38% of patients suffered a bleeding event (nearly one-
half of them due to gastrointestinal bleeding), 8% had a
hemorrhagic stroke, 6% had an ischemic stroke, and 4% had
a pump thrombosis. Multivariate analyses that evaluated
a host of pre-operative demographic and clinical factors
identiﬁed several independent associations with post-
discharge outcomes. The striking ﬁnding is that female sex
was a risk factor for all 4 events (late bleeding, hemorrhagic
stroke, ischemic stroke, and pump thrombosis).
The main strengths of this study are the duration of
follow-up and the large number of patients who were
included in the analysis. As acknowledged by the authors,
the main limitation of this study, beyond the usual concerns
associated with a retrospective analysis of data from un-
blinded clinical trials, is that the analysis was restricted to
evaluating only pre-operative risk factors. Undoubtedly, the
outcomes of interest were strongly inﬂuenced by a multitude
of other peri-operative and post-discharge clinical factors
(e.g., levels of anticoagulation, control of blood pressure,
infections), which will reportedly be analyzed separately.
In this study, women with LVADs had a 67% higher
incidence of post-discharge bleeding than men. Of particular
concern, women also had a nearly 2-fold higher rate of both
hemorrhagic and ischemic strokes than men, a ﬁnding that
could not be attributed to differences in body size. In a
registry of 1,936 patients with LVADsdof whom 21% were
women (n ¼ 401), and 75% had continuous ﬂow devices
(n ¼ 1,055)dHsich et al. (9) also found female sex to be
an independent predictor of time to ﬁrst neurological event
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890during a mean follow-up of 7 months. By contrast, in
a smaller single-institution study of 307 patients with
LVADsdof whom 19% were women (n ¼ 58), and 45%
had HeartMate II devices (n ¼ 140)dKato et al. (10) did
not ﬁnd any sex difference in neurological events during a
mean follow-up of 259  304 days. This discrepant ﬁnding
could simply be due to the small sample size in this study
(underpowered analysis). Alternatively, it is conceivable that
it could be a reﬂection of speciﬁc practice patterns unique
to that institution, which might have attenuated any sex-
speciﬁc disparity in the stroke rate.
Importantly, women enrolled in the HeartMate II BTT
clinical trial (11) and in other LVAD studies (9,12) have a
survival similar to men. Thus, a higher neurological event
rate in women than men, even if conﬁrmed in future studies,
should not dissuade us from considering mechanical circu-
latory support in women. Instead, it should galvanize us to
intensify efforts to elucidate the causes that might underlie
this sex-speciﬁc disparity in adverse neurological events.
Factors that could be considered include sex-speciﬁc alter-
ations in the interaction among the hormonal milieu, the
extent of anticoagulation and platelet inhibition, the he-
modynamic and rheological proﬁles of continuous ﬂow
physiology, and the goals of medical therapy in LVAD
patients. The speciﬁc design features of the LVAD pump
should also be considered, because these might inﬂuence the
design of newer-generation LVADs.
Another important contribution of the analysis by Boyle
et al. (6) is that it highlights the potential clinical utility of
characterizing the subgroups of patients with differing
bleeding (or thrombotic) risks. For example, older men,
particularly those with an ischemic cardiomyopathy and a
low pre-operative hematocrit, have a higher risk of bleeding
than younger men. In current clinical practice, these factors
are not usually taken into consideration when devising an
anticoagulation strategy. Instead, manufacturer recom-
mended target levels of anticoagulation are usually applied
uniformly to patients with LVADs, unless clinical events
(e.g., bleeding) or comorbidities (e.g., atrial ﬁbrillation)
mandate an adjustment to these targets. Identifying the
additional demographic and clinical factors that modulate
the risks of bleeding and thrombosis will enhance our ability
to risk-stratify patients with LVADs. The hope is that by
integrating this information, the anticoagulation and anti-
platelet strategies could be tailored to balance the bleeding
and thrombotic proﬁles of a given patient. Future studies areneeded to evaluate whether such an approach will succeed in
lowering the adverse bleeding and thrombotic events of
patients with LVADs and thus further improve their clinical
outcomes and quality of life.
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